Two case reports of fulminant giant cell myocarditis treated with rabbit anti-thymocyte globulin
© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology..
Background: Giant cell myocarditis (GCM) is an inflammatory form of acute heart failure with high rates of cardiac transplantation or death. Standard acute treatment includes multi-drug immunosuppressive regimens. There is a small but growing number of case reports utilizing rabbit anti-thymocyte globulin in severe cases.
Case summary: Two cases are presented with similar presentations and clinical courses. Both are middle-aged patients with no significant past medical history, who presented with new acute decompensated heart failure that quickly progressed to cardiogenic shock requiring inotropic and mechanical circulatory support. Both underwent endomyocardial biopsies that diagnosed GCM. Both were treated with a multi-agent immunosuppressive regimen, notably including rabbit anti-thymocyte globulin, with subsequent resolution of shock and recovery of left ventricular ejection fraction. Both remain transplant-free and without ventricular arrhythmias at 7 months and 26 months, respectively.
Discussion: In aggregate, these cases are typical of GCM. They add to growing observational data that upfront rabbit anti-thymocyte globulin may reduce morbidity and mortality in GCM, including potentially preventing the need for complex interventions like orthotopic heart transplantation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
European heart journal. Case reports - 8(2024), 4 vom: 02. Apr., Seite ytae128 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bartz-Overman, Colin [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cardiac transplant |
|---|
| Anmerkungen: |
Date Revised 04.04.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1093/ehjcr/ytae128 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM37056720X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM37056720X | ||
| 003 | DE-627 | ||
| 005 | 20240404235557.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240404s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/ehjcr/ytae128 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1365.xml |
| 035 | |a (DE-627)NLM37056720X | ||
| 035 | |a (NLM)38567279 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bartz-Overman, Colin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Two case reports of fulminant giant cell myocarditis treated with rabbit anti-thymocyte globulin |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 04.04.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology. | ||
| 520 | |a Background: Giant cell myocarditis (GCM) is an inflammatory form of acute heart failure with high rates of cardiac transplantation or death. Standard acute treatment includes multi-drug immunosuppressive regimens. There is a small but growing number of case reports utilizing rabbit anti-thymocyte globulin in severe cases | ||
| 520 | |a Case summary: Two cases are presented with similar presentations and clinical courses. Both are middle-aged patients with no significant past medical history, who presented with new acute decompensated heart failure that quickly progressed to cardiogenic shock requiring inotropic and mechanical circulatory support. Both underwent endomyocardial biopsies that diagnosed GCM. Both were treated with a multi-agent immunosuppressive regimen, notably including rabbit anti-thymocyte globulin, with subsequent resolution of shock and recovery of left ventricular ejection fraction. Both remain transplant-free and without ventricular arrhythmias at 7 months and 26 months, respectively | ||
| 520 | |a Discussion: In aggregate, these cases are typical of GCM. They add to growing observational data that upfront rabbit anti-thymocyte globulin may reduce morbidity and mortality in GCM, including potentially preventing the need for complex interventions like orthotopic heart transplantation | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Cardiac transplant | |
| 650 | 4 | |a Cardiogenic shock | |
| 650 | 4 | |a Case reports | |
| 650 | 4 | |a Case series | |
| 650 | 4 | |a Giant cell myocarditis | |
| 650 | 4 | |a Myocarditis | |
| 650 | 4 | |a Rabbit anti-thymocyte globulin | |
| 700 | 1 | |a Li, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Puligandla, Balaram |e verfasserin |4 aut | |
| 700 | 1 | |a Colaco, Nalini |e verfasserin |4 aut | |
| 700 | 1 | |a Steiner, Johannes |e verfasserin |4 aut | |
| 700 | 1 | |a Masha, Luke |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European heart journal. Case reports |d 2017 |g 8(2024), 4 vom: 02. Apr., Seite ytae128 |w (DE-627)NLM290043824 |x 2514-2119 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2024 |g number:4 |g day:02 |g month:04 |g pages:ytae128 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/ehjcr/ytae128 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2024 |e 4 |b 02 |c 04 |h ytae128 | ||